4/A//SEC Filing
Walker Marlan D 4/A
Accession 0001209191-23-027361
CIK 0000025743other
Filed
May 3, 8:00 PM ET
Accepted
May 4, 4:38 PM ET
Size
13.3 KB
Accession
0001209191-23-027361
Insider Transaction Report
Form 4/AAmended
Walker Marlan D
Chief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2023-04-26+1,010→ 14,041 total - Exercise/Conversion
Common Stock
2023-04-26+1,734→ 12,307 total - Sale
Common Stock
2023-04-26$3.64/sh−692$2,518→ 11,615 total - Exercise/Conversion
Restricted Stock Units
2023-04-26−1,010→ 0 totalExercise: $0.00→ Common Stock (1,010 underlying) - Exercise/Conversion
Restricted Stock Units
2023-04-26−1,734→ 3,466 totalExercise: $0.00→ Common Stock (1,734 underlying)
Footnotes (4)
- [F1]The beneficially owned shares have been adjusted as the restricted stock units previously reported as settled on April 12, 2023 were not settled on that date. The restricted stock units settled on April 26, 2023.
- [F2]The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
- [F3]Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in three equal installments annually, becoming fully vested on March 30, 2023.
- [F4]Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025.
Documents
Issuer
TherapeuticsMD, Inc.
CIK 0000025743
Entity typeother
Related Parties
1- filerCIK 0001820187
Filing Metadata
- Form type
- 4/A
- Filed
- May 3, 8:00 PM ET
- Accepted
- May 4, 4:38 PM ET
- Size
- 13.3 KB